The historical western approach of relying on internally-developed blockbuster drugs to drive growth is now under strain. Patent expiries...

The global biopharmaceutical industry entered 2026 facing one of the largest waves of patent expirations in its history. The potential...

There is so much legislative change in the EU and UK in the life sciences sector at the moment that it is sometimes difficult to keep up...

After years in the making, the much-awaited political agreement reached by the EU institutions on the so-called “EU pharma package” will...

The European Commission has published its long-awaited proposal for a regulation to simplify the EU Medical Devices Regulation (“EU...

In this third, and final, article of our three-part series - Thinking early: key legal points for early-stage biotech companies - we are...

In this second article of our three-part series - Thinking early: key legal points for early-stage biotech companies - we cover the...

In this first article of our three-part series - Thinking early: key legal points for early-stage biotech companies - we focus on the key...

On 16 October 2025, Adam Coughlin, Naoise Gaffney and Samuel Munday from Bristows attended TechBio UK, an annual conference hosted by the...

In August, luxury haircare company Olaplex Holdings, Inc. (Olaplex) acquired US biotechnology company Purvala Bioscience, Inc. (Purvala)1...

Although the UK’s new R&D tax relief regime came into force on 1 April 2024, many companies have only now completed their first...

At the start of the year, our editors (Xisca Borrás, Katie Cambrook and Aida Tohala) presented to you the 12th edition of our Biotech...